vs
Innovex International, Inc.（INVX）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
Innovex International, Inc.的季度营收约是REPLIGEN CORP的1.4倍（$273.6M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs 5.1%，领先1.6%），REPLIGEN CORP同比增速更快（13.6% vs 9.1%），过去两年Innovex International, Inc.的营收复合增速更高（46.2% vs 14.4%）
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
INVX vs RGEN — 直观对比
营收规模更大
INVX
是对方的1.4倍
$197.9M
营收增速更快
RGEN
高出4.5%
9.1%
净利率更高
RGEN
高出1.6%
5.1%
两年增速更快
INVX
近两年复合增速
14.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $273.6M | $197.9M |
| 净利润 | $14.0M | $13.3M |
| 毛利率 | 28.9% | 52.5% |
| 营业利润率 | 9.4% | 9.0% |
| 净利率 | 5.1% | 6.7% |
| 营收同比 | 9.1% | 13.6% |
| 净利润同比 | -56.1% | 143.9% |
| 每股收益（稀释后） | $0.20 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INVXRGEN
| Q4 25 | $273.6M | $197.9M | ||
| Q3 25 | $240.0M | $188.8M | ||
| Q2 25 | $224.2M | $182.4M | ||
| Q1 25 | $240.4M | $169.2M | ||
| Q4 24 | $250.7M | $174.1M | ||
| Q3 24 | $151.8M | $154.9M | ||
| Q2 24 | $130.3M | $154.1M | ||
| Q1 24 | $128.0M | $151.3M |
净利润INVXRGEN
| Q4 25 | $14.0M | $13.3M | ||
| Q3 25 | $39.2M | $14.9M | ||
| Q2 25 | $15.3M | $14.9M | ||
| Q1 25 | $14.8M | $5.8M | ||
| Q4 24 | $31.8M | $-30.3M | ||
| Q3 24 | $82.6M | $-654.0K | ||
| Q2 24 | $9.5M | $3.3M | ||
| Q1 24 | $16.4M | $2.1M |
毛利率INVXRGEN
| Q4 25 | 28.9% | 52.5% | ||
| Q3 25 | 31.6% | 53.2% | ||
| Q2 25 | 32.0% | 50.0% | ||
| Q1 25 | 31.8% | 53.6% | ||
| Q4 24 | 33.9% | 26.1% | ||
| Q3 24 | 34.7% | 50.0% | ||
| Q2 24 | 35.3% | 49.8% | ||
| Q1 24 | 38.4% | 49.5% |
营业利润率INVXRGEN
| Q4 25 | 9.4% | 9.0% | ||
| Q3 25 | 26.0% | 8.9% | ||
| Q2 25 | 10.1% | 7.6% | ||
| Q1 25 | 9.1% | 3.9% | ||
| Q4 24 | 10.7% | -17.7% | ||
| Q3 24 | -8.7% | -5.1% | ||
| Q2 24 | 10.0% | 1.0% | ||
| Q1 24 | 17.4% | 1.3% |
净利率INVXRGEN
| Q4 25 | 5.1% | 6.7% | ||
| Q3 25 | 16.3% | 7.9% | ||
| Q2 25 | 6.8% | 8.2% | ||
| Q1 25 | 6.1% | 3.4% | ||
| Q4 24 | 12.7% | -17.4% | ||
| Q3 24 | 54.4% | -0.4% | ||
| Q2 24 | 7.3% | 2.2% | ||
| Q1 24 | 12.8% | 1.4% |
每股收益（稀释后）INVXRGEN
| Q4 25 | $0.20 | $0.24 | ||
| Q3 25 | $0.57 | $0.26 | ||
| Q2 25 | $0.22 | $0.26 | ||
| Q1 25 | $0.21 | $0.10 | ||
| Q4 24 | $-0.03 | $-0.55 | ||
| Q3 24 | $1.99 | $-0.01 | ||
| Q2 24 | $0.30 | $0.06 | ||
| Q1 24 | $0.51 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $767.6M |
| 总债务越低越好 | $18.9M | $542.2M |
| 股东权益账面价值 | $1.1B | $2.1B |
| 总资产 | $1.3B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.02× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资INVXRGEN
| Q4 25 | — | $767.6M | ||
| Q3 25 | — | $748.7M | ||
| Q2 25 | — | $708.9M | ||
| Q1 25 | — | $697.2M | ||
| Q4 24 | — | $757.4M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | $185.6M | $809.1M | ||
| Q1 24 | $202.2M | $780.6M |
总债务INVXRGEN
| Q4 25 | $18.9M | $542.2M | ||
| Q3 25 | $20.1M | $537.9M | ||
| Q2 25 | $34.8M | — | ||
| Q1 25 | $19.7M | — | ||
| Q4 24 | $24.9M | $525.6M | ||
| Q3 24 | $12.4M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益INVXRGEN
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.0B | $2.1B | ||
| Q2 25 | $995.6M | $2.1B | ||
| Q1 25 | $978.4M | $2.0B | ||
| Q4 24 | $958.2M | $2.0B | ||
| Q3 24 | $904.4M | $2.0B | ||
| Q2 24 | $352.5M | $2.0B | ||
| Q1 24 | $344.3M | $2.0B |
总资产INVXRGEN
| Q4 25 | $1.3B | $2.9B | ||
| Q3 25 | $1.3B | $2.9B | ||
| Q2 25 | $1.2B | $2.9B | ||
| Q1 25 | $1.2B | $2.9B | ||
| Q4 24 | $1.2B | $2.8B | ||
| Q3 24 | $1.1B | $2.8B | ||
| Q2 24 | $1.0B | $2.9B | ||
| Q1 24 | $1.0B | $2.8B |
负债/权益比INVXRGEN
| Q4 25 | 0.02× | 0.26× | ||
| Q3 25 | 0.02× | 0.26× | ||
| Q2 25 | 0.03× | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | 0.03× | 0.27× | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $52.2M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | — | $17.6M |
| 自由现金流率自由现金流/营收 | — | 8.9% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | 3.74× | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流INVXRGEN
| Q4 25 | $52.2M | $25.7M | ||
| Q3 25 | $48.4M | $48.1M | ||
| Q2 25 | $59.2M | $28.6M | ||
| Q1 25 | $31.1M | $15.0M | ||
| Q4 24 | $36.3M | $39.2M | ||
| Q3 24 | $21.7M | $49.3M | ||
| Q2 24 | $22.8M | $42.2M | ||
| Q1 24 | $12.6M | $44.7M |
自由现金流INVXRGEN
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $43.4M | ||
| Q2 25 | — | $21.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $33.6M | ||
| Q3 24 | — | $42.3M | ||
| Q2 24 | $16.6M | $37.4M | ||
| Q1 24 | $7.8M | $36.4M |
自由现金流率INVXRGEN
| Q4 25 | — | 8.9% | ||
| Q3 25 | — | 23.0% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 27.3% | ||
| Q2 24 | 12.7% | 24.3% | ||
| Q1 24 | 6.1% | 24.0% |
资本支出强度INVXRGEN
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | 4.7% | 3.1% | ||
| Q1 24 | 3.7% | 5.5% |
现金转化率INVXRGEN
| Q4 25 | 3.74× | 1.93× | ||
| Q3 25 | 1.23× | 3.23× | ||
| Q2 25 | 3.86× | 1.92× | ||
| Q1 25 | 2.11× | 2.57× | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 0.26× | — | ||
| Q2 24 | 2.39× | 12.70× | ||
| Q1 24 | 0.77× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INVX
| Products | $202.7M | 74% |
| Leasing | $42.3M | 15% |
| Services | $28.6M | 10% |
RGEN
暂无分部数据
